PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Recruiting · NCT06530550 · Registry updated 2025-08-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | Hemic and Lymphatic Diseases, Leukemia, Large Granular Lymphocytic, Neoplasms by Histologic Type, T-cell leukemia, T-cell non-Hodgkin lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2025-08-12 | NCT06530550 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 285 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Institute of Hematology & Blood Diseases Hospital | Tianjin | China | 24 |